US2002192826A1PendingUtilityA1

Recombinant AAV vector-based transduction system and use of same

46
Priority: Mar 6, 1996Filed: Aug 12, 2002Published: Dec 19, 2002
Est. expiryMar 6, 2016(expired)· nominal 20-yr term from priority
Inventors:Gerd MaassChristoph BogedainMichael HallekClemens WendtnerDoris Michl
A61P 7/00A61P 43/00A61P 37/00A61P 37/04A61P 25/16A61P 31/00A61P 31/18C12N 15/86A61P 35/00C12N 2750/14143
46
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention relates to a transduction system, comprising (a) a rep-negative AAV vector containing a foreign DNA and (b) a product providing an AAV Rep protein. The invention also relates to the use of the transduction system.

Claims

exact text as granted — not AI-modified
What is claimed is:  
     
         1 . A transduction system comprising: 
 (a) a rep-negative AAV vector containing a foreign DNA; and    (b) a product providing an AAV Rep protein.    
     
     
         2 . The transduction system according to  claim 1 , wherein the rep-negative AAV vector is present as DNA.  
     
     
         3 . The transduction system according to  claim 1 , wherein the foreign DNA is expressible.  
     
     
         4 . The transduction system according to  claim 3 , wherein the foreign DNA is controlled by an inducible promoter.  
     
     
         5 . The transduction system according to  claim 1 , wherein the product is an expressible rep-DNA.  
     
     
         6 . The transduction system according to  claim 5 , wherein the rep-DNA is controlled by an inducible promoter.  
     
     
         7 . The transduction system according to claims  5  or  6 , wherein the rep-DNA is provided within the genome of an AAV virus particle.  
     
     
         8 . The transduction system according to  claim 7 , wherein the genome contains a defective cap gene or a deleted cap gene.  
     
     
         9 . The transduction system according to  claim 7 , wherein the genome contains at least one defective ITR sequence.  
     
     
         10 . The transduction system according to  claim 1 , wherein the product is an AAV Rep protein.  
     
     
         11 . The transduction system according to  claim 1 , wherein the AAV vector is connected with the product.  
     
     
         12 . A method for transducting cells comprising the step of introducing a tranduction system into the cells according to  claim 1 .  
     
     
         13 . The method of  claim 11 , wherein the cells are determined for gene therapy.  
     
     
         14 . The method of  claim 11 , wherein the cells are healthy, diseased or tumor cells.  
     
     
         15 . The method of  claim 11 , wherein the cells are present in an organism.  
     
     
         16 . The method of  claim 11 , wherein the cells are located outside an organism.

Join the waitlist — get patent alerts

Track US2002192826A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.